Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
PaperCitations, authors & open-access status
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 123 citations, 2024 year and hybrid oa status.
123
Citations
2024
Year
hybrid
OA Status